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The Value of Autofluorescence Bronchoscopy Combined
with White Light Bronchoscopy Compared with White
Light Alone in the Diagnosis of Intraepithelial Neoplasia
and Invasive Lung Cancer
A Meta-Analysis
Jiayuan Sun, MD, PhD,* David H. Garfield, MD,† Bing Lam, MD,‡ Jingjing Yan, MD,*
Aiqin Gu, MD,* Jie Shen, MD,* and Baohui Han, MD, PhD*
Objective: To compare the accuracy of autofluorescence bronchos-
copy (AFB) combined with white light bronchoscopy (WLB) versus
WLB alone in the diagnosis of lung cancer.
Methods: The Ovid, PubMed, and Google Scholar databases from
January 1990 to October 2010 were searched. Two reviewers inde-
pendently assessed the quality of the trials and extracted data. The
relative risk for sensitivity and specificity on a per-lesion basis of
AFB  WLB versus WLB alone to detect intraepithelial neoplasia
and invasive cancer were pooled by Review Manager.
Results: Twenty-one studies involving 3266 patients were ulti-
mately analyzed. The pool relative sensitivity on a per-lesion basis
of AFB  WLB versus WLB alone to detect intraepithelial neopla-
sia and invasive cancer was 2.04 (95% confidence interval [CI]
1.72–2.42) and 1.15 (95% CI 1.05–1.26), respectively. The pool
relative specificity on a per-lesion basis of AFB  WLB versus
WLB alone was 0.65 (95% CI 0.59–0.73).
Conclusions: Although the specificity of AFBWLB is lower than
WLB alone, AFB  WLB seems to significantly improve the
sensitivity to detect intraepithelial neoplasia. However, this advan-
tage over WLB alone seems much less in detecting invasive lung
cancer.
Key Words: Autofluorescence bronchoscopy, White light bronchos-
copy, Intraepithelial neoplasia, Invasive lung cancer, Meta-analysis.
(J Thorac Oncol. 2011;6: 1336–1344)
Lung cancer is the leading cause of cancer mortality glob-ally.1 The Third National inquest case study researched by
the Health Ministry of China in 2008 reported that the major
incidence of lung cancer increased 465% in the past 30 years
in China. Although surgery for early stage lung cancers offers
a relatively good prospect of cure, 5-year survival rates for
patients with stage IA disease are 73%; however, for those
with disease at stages II to IV, the rates range from 46 to 9%.2
Currently, only 16% of lung cancers are diagnosed when
disease is localized, and fewer lung cancers are diagnosed at
stage 0, resulting in a combined 5-year survival rate of only
15%.3 Therefore, more sensitive methods for detecting clin-
ically silent lung cancers at the earlier stages are greatly
needed.
White light bronchoscopy (WLB) is a commonly used
diagnostic tool for obtaining tissue for the definitive diagnosis
of lung cancer. However, WLB is limited in its ability to
detect small intraepithelial and microinvasive/preinvasive le-
sions, which may be only a few cells thick and might only
have a surface diameter of a few millimeters. Autofluores-
cence bronchoscopy (AFB) was developed to address this
limitation of WLB.4 AFB has been shown to be a far more
sensitive method of detecting microinvasive/preinvasive le-
sions. However, the literature gives confusing results regard-
ing the sensitivity and specificity of detecting these lesions
when AFB  WLB is compared with WLB alone. For the
proper use of fluorescence bronchoscopy for the diagnosis of
central-type early lung cancer, we systematically reviewed the
literature to summarize the evidence for the value of AFB 
WLB versus WLB alone in the diagnosis of microinvasive/
preinvasive and invasive lung cancer.
MATERIALS AND METHODS
Search Strategy
We searched for articles comparing the value of AFB
WLB versus WLB alone, using search engines in Ovid,
PubMed, and Google Scholar from January 1990 to October
2010. The following key words were used: “AFB” or “fluo-
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rescence bronchoscopy” or “autofluorescence endoscopy” or
“fluorescence endoscopy,” and “WLB” or “conventional
bronchoscopy” or “video bronchoscopy.” We compared
sources to exclude duplicate references (i.e., the same out-
comes reported on the same cohort). Reference lists of in-
cluded studies and review articles were manually searched.
Study Selection
Inclusion criteria were (a) articles were published in
English; (b) AFB and WLB were used in the diagnosis of
intraepithelial neoplasia and invasive lung cancer; (c) histo-
pathology analysis was used as the reference standard; (d) for
per-lesion statistics, sufficient data were presented to calcu-
late the sensitivity and specificity of intraepithelial neoplasia
(moderate/severe dysplasia or carcinoma in situ [CIS]) and
invasive lung cancer; and (e) when data or subsets of data
were presented in more than one article, the article with most
details or the most recent article was chosen.
Data Extraction
Information was extracted from all eligible publica-
tions, independently by two reviewers (J.S. and J.Y.), accord-
ing to the inclusion criteria listed earlier. Disagreement was
resolved by discussion between the two reviewers. Relevant
studies were further examined with Quality Assessment of
Diagnostic Accuracy Studies criteria.5 The following data
were collected from each study: first author’s surname, year
of publication, type of AFB, average subject age, sample size,
patient characteristics, and outcome. To compare the diag-
nostic value for lung cancer of the two types of bronchosco-
pies, we studied the sensitivity and specificity of the two to
diagnose intraepithelial neoplasia and invasive cancer, re-
spectively.
Statistical Analysis
The relative risk (RR) for sensitivity and specificity on
a per-lesion basis of AFB  WLB versus WLB alone to
detect intraepithelial neoplasia or invasive cancer were cal-
culated by Review Manager (RevMan; version 4.2. Copen-
hagen: The Nordic Cochrane Centre, the Cochrane Collabo-
ration). A statistical test with a p less than 0.05 was
considered significant. RR of more than 1 reflects more
sensitivity of in AFB  WLB and vice versa. The results
were generated using the fixed-effects model. A random-
effect model was employed when there was evidence of
significant statistical heterogeneity, generating a more con-
servative estimate. All p values were two sided. All confi-
dence intervals (CIs) had a two-sided probability coverage of
95%. Subgroup analysis was carried out to look at the
diagnostic value of the different types of AFB. An estimate of
potential publication bias was carried out using funnel plot-
ting, in which the standard error of log (RR) of each study
was plotted against its log (RR). An asymmetric plot sug-
gested a possible publication bias. Funnel plot asymmetry
was assessed by the method of Egger’s linear regression test,
a well-established linear regression approach to measure the
funnel plot asymmetry on the natural logarithm scale of
the RR. The significance of the intercept was determined by
the t test suggested by Egger (p  0.05 was considered
representative of statistically significant publication bias)
calculated by using STATA version 10.0 (Stata Corporation,




Two hundred seventy-three reports were originally re-
trieved after electronic searching, and 41 studies were iden-
tified after scanning the titles and abstracts. Twenty studies
were excluded for the following reasons: (a) only AFB was
performed6–8; (b) sufficient data not presented to calculate
sensitivity and specificity9–18; (c) positive result not moder-
ate/severe dysplasia, CIS, or invasive cancer19–21; (d) where
data presented in more than one article, article with fewest
details was excluded22; and (e) studies were not per-lesion
based23–25 (Figure 1).
Characteristics of Included Studies
Twenty-one studies meeting the inclusion criteria were
identified.26–46 WLB was performed in all studies, whereas
different types of AFB were used in different studies. The
light-induced fluorescence endoscopy (LIFE) device (Xillix
Technologies; Vancouver, BC, Canada) was used in 12 stud-
ies. The Storz D-Light system (D-Light, Karl Storz company,
Germany) and Pentax SAFE-1000 systems (Pentax, Tokyo,
Japan) were performed in three studies each. The Pentax
SAFE-3000 system (Pentax), Onco-LIFE device (Xillix
Technologies; Richmond), and PDS-2000 (Hamamatsu Pho-
tonics K.K.,Hamamatsu, Japan) were performed in one study
each. Among the 21, 19 studies had sufficient data to analyze
the RR for sensitivity of WLB  FLB versus WLB alone to
detect intraepithelial neoplasia, whereas 14 studies were used
to analyze the RR for sensitivity of WLB FLB versus WLB
alone to detect invasive cancer. Sixteen studies were used to
analyze the RR for specificity of WLB  AFB versus WLB
FIGURE 1. Flow of identifying the studies. AFB, autofluores-
cence bronchoscopy; WLB, white light bronchoscopy.
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alone (Table 1). The size of the cohorts varied from 30 to
1173, with the total number being 3266 patients.
Publication Bias and Heterogeneity
Publication bias was found according to funnel plot in
the articles enrolled in the analysis of RR for sensitivity
detection of intraepithelial neoplasia (Figure 2; Begg’s test,
p  0.039; Egger’s test, p  0.000). Heterogeneity was
both found in sensitivity to detect intraepithelial neoplasia
and specificity (p  0.05). Therefore, a random effect
model was used for the meta-analysis to obtain a summary
estimate for sensitivity and specificity with 95% CI. To
explore the possible source of heterogeneity, subgroup
analyses were applied. Heterogeneity was also found in the
LIFE subgroup.
Relationship between Prevalence and
Sensitivity
Linear regression suggested that the sensitivity corre-
lated with the prevalence of intraepithelial neoplasia, both for
WLB(r2  0.208, p  0.049) and AFB  WLB(r2  0.214,
p 0.046), but not correlated with the prevalence of invasive
cancer (r2  0.004, p  0.821; r2  0.016, p  0.664).
Meta-Analysis Results
Relative Sensitivity to Detect Intraepithelial
Neoplasia
The pool sensitivity on a per-lesion basis of AFB 
WLB and WLB to detect intraepithelial neoplasia was 84.63
and 42.54%, respectively. The pool relative sensitivity of
AFB WLB versus WLB was 2.04 (95% CI 1.72–2.42) and
was statistically significant (p  0.00001).27–39,41–46 Onco-
LIFE had the highest RR (4.25; 95% CI, 1.56–11.55), but
only one study was included. The analysis in the subgroups
whose enrolled studies were more than one showed that the



























Edell et al.27 Onco-LIFE 62 170 776 41 5.28 9.76 41.46 35 4.51 91.43 100.00 94.00 75.00
Nakanishi et al.33 PDS-2000 69 71 288 29 10.07 27.59 75.86 16 5.56 75.00 93.75 77.37 52.67
Jang et al.35 D-Light 62 113 283 16 5.65 25.00 93.75 NR 93.33 50.00
Lam et al.34 SAFE-1000 60 62 84 11 13.10 54.55 100.00 1 1.19 100.00 100.00 NR
Ikeda et al.36 SAFE-3000 68 154 166 48 28.92 66.67 100.00 30 18.07 100.00 100.00 NR
Häussinger et al.38 D-Light 59 1173 2907 53 1.82 57.89 82.35 NR 62.12 58.38
Chhajed et al.37 LIFE 67 151 343 63 18.37 63.49 96.83 20 5.83 100.00 100.00 53.46 17.69
Moro-Sibilot et al.39 LIFE 60 244 354 42 11.86 35.71 85.71 39 11.02 74.36 76.92 96.34 82.78
van Rens et al.42 LIFE 66 72 88 15 17.05 20.00 100.00 1 1.14 100.00 100.00 NR
Shibuya et al.41 LIFE 68 64 212 45 21.23 68.89 91.11 21 9.91 100.00 100.00 65.75 31.51
Hirsch et al.40 LIFE 68 55 391 NR NR 77.64 29.39
Vermylen et al.43 LIFE 59 34 142 16 11.27 25.00 93.75 NR 86.51 20.63
Weigel et al.26 LIFE 65 36 89 NR NR 86.75 48.19
Ikeda et al.31 LIFE 64 158 262 84 32.06 58.33 100.00 43 16.41 100.00 100.00 62.22 44.44
Venmans et al.32 LIFE 65 95 681 79 11.60 59.49 84.81 21 3.08 100.00 100.00 84.85 60.41
Kakihana et al.29 SAFE-1000 NR 72 147 55 37.41 52.73 100.00 24 16.33 100.00 100.00 NR
Häußinger et al.28 D-Light 62 56 264 7 2.65 28.57 71.43 36 13.64 80.56 83.33 93.21 86.43
Horvath et al.30 SAFE-1000 51 60 146 5 3.42 0.00 100.00 NR 91.49 76.60
Lam et al.44 LIFE 63 173 700 102 14.57 8.82 55.88 40 5.71 65.00 95.00 90.32 65.95
Ikeda et al.45 LIFE NR 30 77 28 36.36 35.71 100.00 13 16.88 92.31 100.00 NR
Lam et al.46 LIFE NR 223 451 113 25.06 38.94 84.07 NR 91.12 81.36
AFB, autofluorescence bronchoscopy; WLB, white light bronchoscopy; NR, not reported.
FIGURE 2. Funnel plot of 19 studies included in the analy-
sis of relative risk (RR) for sensitivity of autofluorescence
bronchoscopy  white light bronchoscopy (WLB) versus
WLB to detect intraepithelial neoplasia.
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highest RR was 2.16 in D -Light (95% CI 1.06–4.39).
SAFE-1000 was the lowest at 1.88 (95% CI 1.50–2.36), and
the LIFE RR was 2.10 (95% CI 1.66–2.66). The RR of the
other subgroups was as follows: SAFE-3000, 1.49 (95% CI
1.22–1.83) and PDS-2000, 2.75 (95% CI 1.47–5.13). The test
of heterogeneity for the 19 studies was significant (p 
0.00001). Thus, RR was calculated using a random-effect
model (Figure 3).
FIGURE 3. Forest plot of relative risk for subgroup and overall sensitivity of autofluorescence bronchoscopy (AFB)  white
light bronchoscopy (WLB) versus WLB to detect intraepithelial neoplasia. CI, confidence interval.
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Relative Sensitivity to Detect Invasive Cancer
The pool sensitivity on a per-lesion basis of AFB 
WLB versus WLB to detect invasive cancer was 94.71 and
88.53%, respectively. The pool relative sensitivity of AFB 
WLB versus WLB was 1.15 (95% CI 1.05–1.26) and was
statistically significant (p  0.003).27–29,31–34,36,37,39,41,42,44,45
Only the RR of LIFE was statistically significant (p  0.01),
with a value of 1.21 (95% CI 1.04–1.40) among the sub-
groups. The RR of other subgroups was not statistically
significant (p 0.05). PDS-2000 had the highest RR (1.25, 95%
CI 0.92–1.70), but only one study was enrolled. The RR of the
other subgroups was as follows: D-Light, 1.03 (95% CI 0.83–
1.29) and Onco-LIFE, 1.09 (95%CI 0.97–1.22). The RR of both
SAFE-1000 and SAFE-3000 were 1. The test of heterogeneity
for the 14 studies was not significant (p  0.23). Thus, the RR
was calculated using a fixed-effect model (Figure 4).
FIGURE 4. Forest plot of relative risk (RR) for subgroup and overall sensitivity of autofluorescence bronchoscopy (AFB) 
white light bronchoscopy (WLB) versus WLB to detect invasive cancer. CI, confidence interval.
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Relative Specificity
The pool specificity on a per-lesion basis of AFB 
WLB versus WLB was 60.94 and 79.70%, respectively. The
pool relative specificity on a per-lesion basis of AFBWLB
versus WLB was 0.65 (95% CI 0.59–0.73) and was statisti-
cally significant (p  0.00001).26–28,30–33,35,37–41,43,44,46 The
RR of the subgroups were as follows: LIFE, 0.56 (95% CI
0.47–0.68); D-Light, 0.78 (95% CI 0.62–0.99); SAFE-1000,
0.84 (95% CI 0.75–0.93); Onco-LIFE, 0.80 (95% CI 0.76–
0.84); and PDS-2000, 0.68 (95% CI 0.59–0.78). The test of
heterogeneity for the 16 studies was significant (p 
0.00001). Thus, the RR was calculated using a random-effect
model (Figure 5).
Adverse Effects
Adverse effects were reported in two studies. In one
study,27 reported adverse effects were seen in nine patients.
All adverse effects were commensurate with bronchoscopy,
with none being attributable to the AFB devices. Serious
complications include fever and hypoxia, resulting in hospi-
talization in four patients. Ikeda et al.36 reported only minor
adverse effects such as faint blood-tinged sputum and mild
FIGURE 5. Forest plot of relative risk (RR) for subgroup and overall specificity of autofluorescence bronchoscopy (AFB) 
white light bronchoscopy (WLB) versus WLB. CI, confidence interval.
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cough, commonly associated with routine bronchoscopic ex-
amination, with there being no specific relation to the AFB
examination.
DISCUSSION
Detection of cancers at an early stage, followed by
complete surgical resection, is the only curative treatment
approach currently available for the majority of lung cancer
patients. Advances in bronchoscopy47 and the use of sputum
cytology have helped to increase the detection of central-type
early lung cancer. WLB is usually used in the detection of
lung cancer. Nevertheless, although this type of bronchos-
copy can detect early lung cancer, the detection of preinva-
sive lesions is difficult even for experienced bronchoscopists.
One study48 showed that only 29% of CIS lesions were
visible to experienced bronchoscopists using WLB.
According to our meta-analysis, AFB  WLB can
effectively and significantly improve the sensitivity to detect
only intraepithelial neoplasia compared with WLB alone, the
pool relative sensitivity of AFB  WLB versus WLB to
detect intraepithelial neoplasia is 2.04. It has been reported in
Bronchial Intraepithelial Neoplasia/Early Central Airways
Lung Cancer, ACCP Evidence-Based Clinical Practice
Guidelines (2nd edition) that the pool sensitivity on a per-
lesion basis of AFB  WLB and WLB to detect intraepithe-
lial neoplasia was 80 and 40%, respectively; the pool speci-
ficity was 60 and 81%, respectively; and the pool relative
sensitivity of AFB  WLB versus WLB was 2.49 Although
the literatures enrolled in our meta-analysis were 38.9% same
to this guideline for the different enrollment standard and the
results of the guideline were not obtained by meta-analysis,
our conclusions were surprisingly similar. Thus, we believe
that our results are credible.
Although the sensitivity of AFB combined with WLB
to detect invasive cancer was improved, its RR was only 1.15,
which is much lower than the RR for sensitivity to detect
intraepithelial neoplasia. If one is screening for invasive
cancer, then, perhaps only WLB is needed. It is less expen-
sive, easier to perform, and can be done in more centers and
used more widely in populations whose chest radiology
evidences are suspicious of central airways lesion. Thus,
using WLB alone would seem to be cost effective.
The disadvantage of AFB is the lower specificity com-
pared with WLB. The specificities of AFB  WLB in this
meta-analysis were all decreased, compared with WLB alone,
and the specificity of AFB  WLB was only 65% of WLB
alone. The reason for the low specificity is that AFB has
difficulty in distinguishing between preinvasive lesions and
other benign epithelial changes such as bronchitis, which is
frequently present in patients whose sputum cytology is
suspicious or positive for malignancy.41 Some anthropic fac-
tors, such as severe coughing during AFB examination or
AFB, were performed in patients after brushing or biopsy by
recent WLB; all can result in false positive. The low speci-
ficity of AFB is also problematic because more biopsies are
needed, resulting in greater cost and potential patient harm.
Bronchoscopic devices subsequent to LIFE have made
many improvements. SAFE 1000 system uses a xenon lamp,
instead of the laser used in the LIFE system. A new version
(SAFE-3000), incorporating single action image switching
and simultaneous display, is now available. Storz D-light and
Onco-LIFE systems combine autofluorescence and reflected
light. AFI (Olympus Medical System Corp., Tokyo, Japan)
has developed a display of a composite image, integrating
three signals: an autofluorescence signal plus reflected green
(G) and red (R) light signals. AFI will display a light green
image for normal epithelium and blue or magenta for an
abnormal fluorescence, depending on the condition of abnor-
mal epithelium. This may be more objective than the LIFE
system, under which normal areas appear as green, whereas
areas suspicious for moderate dysplasia or greater have a
definite brown or brownish-red color. In one study, the AFI
system had better sensitivity (80%) and specificity (83%)
than the LIFE system.8 Also, some studies reported that AFI
has a higher sensitivity and specificity than WLB.7,17 How-
ever, these studies were not enrolled in our analysis because
they did not match our inclusion criteria. In addition to
equipment upgrades, quantitative methods have also been
reported to improve the sensitivity and specificity for diag-
nosing lung cancer. One study reported about AFB (PDS-
2000) images that were analyzed using Photoshop 6.0 (Adobe
Systems Inc., San Jose, CA). Normal and abnormal bronchial
parts were defined. Color histograms for red, green, and blue
were generated in each area, using a histogram tool. Then the
R:G ratio was calculated.33
Our findings are limited because of data heterogeneity.
Possible reasons are as follows: (1) studies enrolled in the
meta-analysis were over a long time span 1994 to 2009; (2)
use of different types of AFB, but mainly LIFE (57.14%);
studies of other types of AFB were few or not match our
enrollment standard; (3) study populations were different in
many articles, with some having patients with known or
suspected lung cancer, whereas others had patients only with
high risk of lung cancer, resulting in different prevalence of
lesions. Linear regression suggested that the sensitivity cor-
related with the prevalence of intraepithelial neoplasia, both
for WLB and AFB WLB. Therefore, an important issue is
to define a population recommended for AFB examination.
Thoracic computed tomography is a sensitive method for
detecting early lung cancer but has a high false-positive rate
and is not as sensitive for detecting central preinvasive and
microinvasive cancers. Conventional sputum cytology is
hampered by a low sensitivity, but this can be improved by
using DNA analyses of sputum slides, using automated spu-
tum cytology, but with a modest reduction of specificity.50–53
Thus, patients with positive automated sputum cytology, but
with chest imaging studies showing no localizing abnormal-
ity, may be a defined population recommended for having an
AFB examination for detection of early lung cancer. The
efficiency of AFB in detecting early lung cancer may thereby
be enhanced in the setting of such dual screening.
In conclusion, compared with application of WLB
alone, AFB  WLB seems to significantly improve the
sensitivity and ability to detect intraepithelial neoplasia.
However, this advantage over WLB alone seems much less in
detecting invasive lung cancer. Although the specificity of
Sun et al. Journal of Thoracic Oncology • Volume 6, Number 8, August 2011
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AFB is lower than WLB, the development of newer instruments
of AFB and the application of quantitation methods might
improve the specificity of AFB, which would shorten examina-
tion time, reduce biopsy site size, and decrease risk and cost.
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